Chang, Kung-Chi http://orcid.org/0000-0002-7724-5546
Diermeier, Sarah D. http://orcid.org/0000-0002-6120-2744
Yu, Allen T.
Brine, Lily D.
Russo, Suzanne
Bhatia, Sonam http://orcid.org/0000-0002-0124-2621
Alsudani, Habeeb
Kostroff, Karen
Bhuiya, Tawfiqul
Brogi, Edi http://orcid.org/0000-0003-4737-8468
Pappin, Darryl J.
Bennett, C. Frank
Rigo, Frank
Spector, David L. http://orcid.org/0000-0003-3614-4965
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (5P01CA013106-Project 3, 1K99CA215362)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 27 January 2020
Accepted: 20 November 2020
First Online: 22 December 2020
Competing interests
: D.L. Spector is a consultant to, and receives research support from, Ionis Pharmaceuticals. C.F.B. is the executive Vice President, Chief Scientific Officer at Ionis Pharmaceuticals. F.R. is the Vice President, drug discovery at Ionis Pharmaceuticals. The remaining authors declare no competing interests.